Nuevo medicamento topico para la Dermatitis Atopica.

Novel Compound Promising Topical Treatment For Mild To Moderate Atopic Dermatitis.

HCP Live (7/14) reports that "a novel compound has emerged from two phase III clinical trials as a promising topical treatment for mild to moderate atopic dermatitis (AD)." Researchers found that "crisaborole (Anacor Pharmaceuticals), a nonsteroidal phosphodiesterase 4 (PDE4) inhibitor, showed safety and efficacy in two identically designed, vehicle-controlled double-blind studies." The findings were published online in the Journal of the American Academy of Dermatology.

Benjamin Hidalgo-Matlock

Skin Care Physicians of Costa Rica

4000-1054

2208-8206

Please excuse the shortness of this message, as it has been sent from a mobile device.